{
    "id": 24026,
    "cites": 61,
    "cited_by": 1,
    "reference": [
        "Acemoglu, Daron, and Joshua Linn. \"Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry.\" Quarterly journal of economics 3 (2004): 1049-1090.",
        "Berndt, E.R., Conti, R.M. and Murphy, S.J., 2017. The Landscape of US Generic Prescription Drug Markets, 20042016 (No. w23640). National Bureau of Economic Research.",
        "Bespalov, Anton, et al. \"Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets.\" Nature Reviews Drug Discovery (2016).",
        "Berndt, Ernst R., and Mark R. Trusheim. \"Biosimilar and Biobetter Scenarios for the US and Europe: What Should We Expect?.\" In Biobetters, pp. 315-360. Springer New York, 2015.",
        "Budish, Eric, Benjamin N. Roin, and Heidi Williams. \"Do firms underinvest in long-term research? Evidence from cancer clinical trials.\" The American economic review 105.7 (2015): 2044-2085.",
        "Chandra, A. and Garthwaite, C., 2017. The Economics of Indication-Based Drug Pricing. New England Journal of Medicine, 377(2), pp.103-106.",
        "Costinot, A., Donaldson, D., Kyle, M. and Williams, H., 2016. The more we die, the more we sell? a simple test of the home-market effect (No. w22538). National Bureau of Economic Research.",
        "Cohen, Joshua P., and Abigail E. Felix. \"Personalized medicine\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s bottleneck: diagnostic test evidence and reimbursement.\" Journal of personalized medicine 4.2 (2014): 163-175.",
        "De Angelis, Catherine, et al. \"Clinical trial registration: a statement from the International Committee of Medical Journal Editors.\" New England Journal of Medicine 351.12 (2004): 1250-1251.",
        "Dubois, Pierre, Olivier de Mouzon, Fiona Scot Morton, and Paul Seabright. \"Market size and pharmaceutical innovation.\" The RAND Journal of Economics 46, no. 4 (2015): 844-871.",
        "Dzau, V.J., Ginsburg, G.S. Realizing the Full Potential of Precision Medicine in Health and Health Care. JAMA. 2016; 316(16):1659\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1660.",
        "FDA, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Guidance for Industry: Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d (Draft Guidance) U.S. Department of Health and Human Services, Food and Drug Administration (2004).",
        "FDA, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Guidance for Industry E15 Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, 24 Genomic Data and Sample Coding Categories.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d U.S. Department of Health and Human Services, Food and Drug Administration (2008).",
        "Fridlyand, J., Simon, R., Walrath, J., Roach, N., Buller, R., Schenkein, D., Flaherty, K., Allen, J., Sigal, E., & Scher, H. 2013, Considerations for the successful co-development of targeted cancer therapies and companion diagnostics, Nature Reviews Drug Discovery, 12, 10, pp. 743-755 Guedj, I., & Scharfstein, D. (2004). Organizational scope and investment: Evidence from the drug development strategies and performance of biopharmaceutical firms (No. w10933). National Bureau of Economic Research.",
        "Hegde, Deepak, and Bhaven Sampat. \"Can private money buy public science? Disease group lobbying and federal funding for biomedical research.\" Management Science 61, no. 10 (2015): 2281-2298.",
        "International Trade Administration, Department of Commerce. 2016 ITA Pharmaceuticals Top Markets Report.\" (2016).",
        "Kanavos, Panos, Alessandra Ferrario, Sotiris Vandoros, and Gerard F. Anderson. \"Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs.\" Health affairs 32, no. 4 (2013): 753-761.",
        "Kao, Jennifer L. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093R&D Decisions for New Medical Technologies: Evidence from New Use Approvals and Off-Label Uses.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working Paper (2017).",
        "Phyo, Aung Pyae, et al. \"Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.\" The Lancet Infectious Diseases 16.1 (2016): 61-69.",
        "Rock Health \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u00932016 Year End Funding Report\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Available at https://rockhealth.com/reports/2016-yearend -funding-report-a-reality-check-for-digital-health (2017).",
        "Scott Morton, Fiona M. \"Entry decisions in the generic pharmaceutical industry.\" The Rand journal of economics (1999): 421-440.",
        "Scott Morton, Fiona M., Ariel Dora Stern, and Scott Stern. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The impact of the entry of biosimilars: evidence from Europe.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Harvard Business School Working Paper No. 16-141, 2016.",
        "Stern, Ariel D., Brian M. Alexander, and Amitabh Chandra, 2017. How economics can shape precision medicines. Science, 355(6330), pp.1131-1133.",
        "Stern, Ariel D., Brian M. Alexander, and Amitabh Chandra. \"Innovation Incentives and Biomarkers.\" Clinical Pharmacology & Therapeutics (2017). Figures Figure 1: Clinical trials over time 0 2,000 4,000 6,000 Number of trials 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 2 0 1 0 2 0 1 1 2 0 1 2 2 0 1 3 2 0 1 4 2 0 1 5 2 0 1 6",
        "Number of registered Phase I\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0099III trials (1995\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u00992016) Phase I Phase II Phase III 0 200 400 600 800 1000 1200 1400 1600 1800 2000 Growth (%) 1995 2000 2005 2010 2015 Start year Phase I Phase II Phase III Growth in number of registered Phase I\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0099III trials since 1995 Figure 2: Clinical trials using biomarkers 0 1,000 2,000 3,000 4,000 Number of trials 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 2 0 1 0 2 0 1 1 2 0 1 2 2 0 1 3 2 0 1 4 2 0 1 5 2 0 1 6",
        "Number of registered Phase I\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0099III trials using at least one biomarker Phase I Phase II Phase III 0 10 20 30 40 50 60 70 80 90 100 Share of trials (%) 1995 2000 2005 2010 2015 Start year Phase I Phase II Phase III Share of trials using at least one biomarker Figure 3: Clinical trials for LPMs 0 100 200 300 400 500 Number of trials 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 2 0 1 0 2 0 1 1 2 0 1 2 2 0 1 3 2 0 1 4 2 0 1 5 2 0 1 6",
        "Number of registered LPM (generous definition) trials by phase Phase I Phase II Phase III 0 1 2 3 4 5 6 7 8 9 10 11 12 Share of trials (%) 1995 2000 2005 2010 2015 Start year Phase I Phase II Phase III Share of trials with LPM biomarkers (generous definition) 0 100 200 300 400 500 Number of trials 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 2 0 1 0 2 0 1 1 2 0 1 2 2 0 1 3 2 0 1 4 2 0 1 5 2 0 1 6",
        "Number of registered LPM (generous definition) trials by phase: cancer trials Phase I Phase II Phase III 0 5 10 15 20 25 30 35 40 45 50 Share of trials (%) 1995 2000 2005 2010 2015 Start year Phase I Phase II Phase III Share of cancer drug trials with LPM biomarkers (generous definition) 0 100 200 300 400 Number of trials 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 2 0 1 0 2 0 1 1 2 0 1 2 2 0 1 3 2 0 1 4 2 0 1 5 2 0 1 6",
        "Number of registered LPM (restrictive definition) trials by phase: cancer trials Phase I Phase II Phase III 0 5 10 15 20 25 30 35 40 45 50 Share of trials (%) 1995 2000 2005 2010 2015 Start year Phase I Phase II Phase III Share of cancer drug trials with LPM biomarkers (restrictive definition) Figure 6: Clinical trials for LPMs, U.S. trials only 0 50 100 150 200 250 Number of trials 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 2 0 1 0 2 0 1 1 2 0 1 2 2 0 1 3 2 0 1 4 2 0 1 5 2 0 1 6",
        "Number of registered LPM (generous definition) trials by phase: US trials Phase I Phase II Phase III 0 2 4 6 8 10 12 14 16 18 20 Share of trials (%) 1995 2000 2005 2010 2015 Start year Phase I Phase II Phase III Share of US drug trials with LPM biomarkers (generous definition) 0 50 100 150 200 250 Number of trials 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 2 0 1 0 2 0 1 1 2 0 1 2 2 0 1 3 2 0 1 4 2 0 1 5 2 0 1 6",
        "Number of registered Phase I\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0099III US trials (1995\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u00992016) Phase I Phase II Phase III 0 1000 2000 3000 4000 5000 6000 7000 8000 9000 Growth (%) 1995 2000 2005 2010 2015 Start year Phase I Phase II Phase III Growth in number of registered Phase I\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0099III US trials since 1995 0 1,000 2,000 3,000 4,000 Number of trials 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 2 0 1 0 2 0 1 1 2 0 1 2 2 0 1 3 2 0 1 4 2 0 1 5 2 0 1 6",
        "Number of registered Phase I\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0099III non\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0099US trials (1995\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u00992016) Phase I Phase II Phase III 0 1000 2000 3000 4000 5000 6000 7000 8000 9000 Growth (%) 1995 2000 2005 2010 2015 Start year Phase I Phase II Phase III Growth in number of registered Phase I\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0099III non\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0099US trials since 1995 Appendix Figure B: U.S. Clinical trials using biomarkers 0 200 400 600 800 1,000 Number of trials 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 2 0 1 0 2 0 1 1 2 0 1 2 2 0 1 3 2 0 1 4 2 0 1 5 2 0 1 6",
        "Number of registered Phase I\u00c3\u00a2\u00cb\u0086\u00e2\u0080\u0099III US trials using at least one biomarker Phase I Phase II Phase III 0 10 20 30 40 50 60 70 80 90 100 Share of trials (%) 1995 2000 2005 2010 2015 Start year Phase I Phase II Phase III Share of US trials using at least one biomarker Appendix Figure C: U.S. Clinical trials for LPMs 0 50 100 150 200 250 Number of trials 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 2 0 1 0 2 0 1 1 2 0 1 2 2 0 1 3 2 0 1 4 2 0 1 5 2 0 1 6",
        "Number of registered US LPM (generous definition) trials by phase Phase I Phase II Phase III 0 2 4 6 8 10 12 14 16 18 20 Share of trials (%) 1995 2000 2005 2010 2015 Start year Phase I Phase II Phase III Share of US trials with LPM biomarkers (generous definition) 0 50 100 150 200 250 Number of trials 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 2 0 1 0 2 0 1 1 2 0 1 2 2 0 1 3 2 0 1 4 2 0 1 5 2 0 1 6",
        "Number of registered US LPM (generous definition) trials by phase: cancer trials Phase I Phase II Phase III 0 5 10 15 20 25 30 35 40 45 50 55 60 Share of trials (%) 1995 2000 2005 2010 2015 Start year Phase I Phase II Phase III Share of US cancer drug trials with LPM biomarkers (generous definition) 0 50 100 150 200 250 Number of trials 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 2 0 1 0 2 0 1 1 2 0 1 2 2 0 1 3 2 0 1 4 2 0 1 5 2 0 1 6",
        "1)! Sweat chloride may be used as a diagnostic biomarker to confirm cystic fibrosis (Farrell et al. 2008).",
        "2)! Glomerular filtration rate (GFR) may be used as a diagnostic biomarker to identify patients with chronic kidney disease (National Kidney Foundation 2002). Monitoring Biomarker A biomarker measured serially for assessing status of a disease or medical condition or for evidence of exposure to (or effect of) a medical product or an environmental agent.",
        "1)! HIV-RNA may be used as a monitoring biomarker to measure and guide treatment with antiretroviral therapy (ART) (AIDSinfo 2007).",
        "2)! Serial measurements of symphysis-fundal height during pregnancy can be used during antenatal screening to detect fetal growth disturbances (Papageorghiou et al. 2016). Pharmacodynamic / Response Biomarker A biomarker used to show that a biological response has occurred in an individual who has been exposed to a medical product or an environmental agent.",
        "1)! Circulating B lymphocytes may be used as a pharmacodynamic /response biomarker when evaluating patients with systemic lupus erythematosus to assess response to a B-lymphocyte stimulator inhibitor (Stohl and Hilbert 2012).",
        "2)! Urinary level of glycosaminoglycans may be used as a pharmacodynamic/response biomarker when evaluating the effect of enzyme replacement therapy for patients with mucopolysaccharidosis type 1 (Jameson et al. 2016). Predictive Biomarker A biomarker used to identify individuals who are more likely than similar individuals without the biomarker to experience a favorable or unfavorable effect from exposure to a medical product or an environmental agent.",
        "1)! Certain cystic fibrosis transmembrane conductance regulator (CFTR) mutations may be used as predictive biomarkers in clinical trials evaluating treatment for cystic fibrosis, to select patients more likely to respond to particular treatments (Davies et al. 2013).",
        "2)! Human leukocyte antigen allele (HLA)\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009cB*5701 genotype may be used as a predictive biomarker to evaluate human immunodeficiency virus (HIV) patients before abacavir treatment, to identify patients at risk for severe skin reactions (AIDSinfo 2007). Prognostic Biomarker A biomarker used to identify likelihood of a clinical event, disease recurrence or progression in patients who have the disease or medical condition of interest.",
        "1)! Breast Cancer genes 1 and 2 (BRCA1/2) mutations may be used as prognostic biomarkers when evaluating women with breast cancer, to assess the likelihood of a second breast cancer (Basu et al. 2015).",
        "2)! Gleason score may be used as a prognostic biomarker when evaluating patients with prostate cancer to assess the likelihood of cancer progression (Epstein et al. 2016; Gordetsky and Epstein 2016).",
        "Safety Biomarker A biomarker measured before or after an exposure to a medical product or an environmental agent to indicate the likelihood, 1)! Hepatic aminotransferases and bilirubin may be used as safety biomarkers when evaluating potential hepatotoxicity (Senior 2014). ii presence, or extent of toxicity as an adverse effect.",
        "2)! Serum creatinine may be used as a safety biomarker when evaluating patients on drugs that affect kidney function to monitor for nephrotoxicity (Wasung et al. 2015). Susceptibility / Risk Biomarker: A biomarker that indicates the potential for developing a disease or medical condition in an individual who does not currently have clinically apparent disease or the medical condition.",
        "1)! Factor V Leiden may be used as a susceptibility/risk biomarker to identify individuals with a predisposition to develop deep vein thrombosis (DVT) (Kujovich 2011).",
        "2)! Infection with certain human papillomavirus (HPV) subtypes may be used as a susceptibility/risk biomarker to identify individuals with a predisposition to develop cervical cancer (Khan et al. 2005; Schiffman et al. 2011). Note: Some examples of biomarkers cited in this appendix may be applicable for more than one type of biomarker. For example, in some cases predictive biomarkers used to identify individuals who are more likely to experience a favorable effect from a drug can also be used as diagnostic biomarkers in the initial detection or confirmation of the disease (e.g. CFTR mutations in Cystic Fibrosis). iii APPENDIX B Effects of uniform pricing versus indication-based pricing.",
        "From Chandra, A. and Garthwaite, C. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Economics of Indication-Based Drug Pricing.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New England Journal of Medicine, 377(2), pp.103-106. Copyright  (2017) Massachusetts Medical Society. Reprinted with permission.",
        "Panel B of the graph represents the same set scenarios with respect to the distribution of patients and valuations but allows for indication based pricing by the manufacturer. The scenario presented is an extreme example where a monopoly provider is able to set the price exactly at the willingness to pay of the Chandra'A,'Garthwaite'C.'N'Engl'J'Med'2017:377:103=106.",
        "December 1, 2007. Accessed October 2016. Available at: https://aidsinfo.nih.gov/guidelines /html/1/adult-and-adolescent-arv-guidelines/7/hla-b--5701-screening Basu NN, Ingham S, Hodson J, Lalloo F, Bulman M, Howell A, Evans DG. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. Fam Cancer. 2015 Dec;14(4):531\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c8. doi: 10.1007/s10689-015-9825-9. PubMed PMID: 26239694.",
        "ClinicalTrials.gov. History, Policies, and Laws. July, 2017. Accessed August 2017. Available at: https://clinicaltrials.gov/ct2/about-site/history Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 Feb;40(2):244\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c52. doi: 10.1097/PAS.0000000000000530. PubMed PMID: 26492179.",
        "Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW 3rd. Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008 Aug;153(2):S4\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009cS14. doi: 10.1016/j.jpeds.2008.05.005. PubMed PMID: 18639722.",
        "FDA-NIH Biomarker Working Group. \"BEST (Biomarkers, EndpointS, and other Tools) Resource.\" (2016). Gordetsky J, Epstein J. Grading of prostatic adenocarcinoma: current state and prognostic implications.",
        "Jameson E, Jones S, Remmington T. Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I. Cochrane Database Syst Rev. 2016 Apr 1;4:CD009354. doi: 10.1002/14651858.CD009354.pub4. PubMed PMID: 27033167.",
        "Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005 Jul 20;97(14):1072\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c9. doi: 10.1093/jnci/dji187. PubMed PMID: 16030305.",
        "Kujovich JL, Factor V. Leiden thrombophilia. Genet Med. 2011 Jan;13(1):1\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c16. doi: 10.1097/GIM.0b013e3181faa0f2. PubMed PMID: 21116184.",
        "Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, Buckland J, Sherman ME, Rydzak G, Kirk P, Lorincz AT, Wacholder S, Burk RD. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1398\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c409. doi: 10.1158/10559965. EPI-11-0206. PubMed PMID: 21602310.",
        "Senior JR. Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. Drug Saf. 2014 Nov;37 Suppl 1:S9\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c17. doi: 10.1007/s40264-0140182 -7. PubMed PMID: 25352324. Stohl W, Hilbert DM. The discovery and development of belimumab: the anti-BLyS-lupus connection.",
        "Wasung ME, Chawla LS, Madero M. Biomarkers of renal function, which and when? Clin Chim Acta. 2015 Jan 1;438:350\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c7. doi: 10.1016/j.cca.2014.08.039. PubMed PMID: 25195004."
    ]
}